RxDoctor Payments Data

Dana Watkins

Physician Assistant · Columbia, SCNPI 1912693169

Payments from drug & device makers

$1,075in general payments, 2019–2025

Across 43 payments — averaging $25.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$186
  • AstraZeneca$170
  • Boston Scientific$156
  • Novartis$82
  • Boehringer Ingelheim$76
  • Esperion Therapeutics, Inc.$67
  • plus $339 from 10 others

What the payments were for

  • Food & beverage$97691%
  • Education$999%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,075 in reported general payments places this provider in the 65th percentile of 1,852 physician assistant providers in South Carolina.

See all physician assistant providers in South Carolina

Medicare billing

Part B allowed, 2024
$11,083
Medicare patients
99
Services billed
112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban190$178,908
EntrestoSacubitril/Valsartan92$105,802
Repatha SureclickEvolocumab90$84,146
JardianceEmpagliflozin64$81,604
FarxigaDapagliflozin Propanediol45$44,178
XareltoRivaroxaban33$42,761
Praluent PenAlirocumab24$21,200
OzempicSemaglutide12$11,150
Rosuvastatin Calcium130$3,547
Atorvastatin Calcium185$3,239
Valsartan71$2,804
Metoprolol Succinate167$2,782
Omega-3 Acid Ethyl Esters11$1,543
Carvedilol154$1,484
Diltiazem 24hr Er (Cd)Diltiazem Hcl26$1,373

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$52$178,908190 claims
NovartisEntresto$82$105,80292 claims
Boehringer IngelheimJardiance$76$81,60464 claims
AstraZenecaFarxiga$170$44,17845 claims
Johnson & JohnsonXarelto$15$42,76133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,852 physician assistant providers in South Carolina.

Other physician assistant in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →